Tissue Engineering
Aerosol nutrient delivery in tissue-engineering bioreactors — addressing the oxygen-gradient constraint
Research & publications
Science in the open
Peer-reviewed science • Active publication program • Independent replication • Partner-ready evidence
Publication program
A structured publication program, in three waves
The scientific team is actively publishing. The program is sequenced so each contribution documents the science, reinforces the IP position, and adds to the partner-ready evidence package.
Wave 1
Foundation
The lead production IP, the aerosol bioreactor, and the historical fingertip technical proof model.
Wave 2
Expansion
Production workflow and additional clinical indications across the platform.
Wave 3
Clinical & platform
Independent replication outcomes and a platform review, including the longer-horizon monitoring layer.
Selected publication targets
- Biofabrication
- Biomaterials
- Tissue Engineering
- npj Regenerative Medicine
- Acta Biomaterialia
- Cytotherapy
Publication status
The record so far
Published · OnlineFirst · 23 May 2026
Tissue Engineering Part B: Reviews
Clinical Bioprinting Is Coming of Age: Ex Vivo Versus In Vivo — Response to the Letter to the Editor
Mironov, V.A. & Kovalev, A.V. · Tissue Engineering Part B: Reviews · OnlineFirst, 23 May 2026
Regentron's scientific team engaged the active scholarly debate on the trajectory of clinical bioprinting — the strategic distinction between ex vivo and in vivo approaches. Vladimir Mironov and Alexey Kovalev authored this correspondence in Tissue Engineering Part B: Reviews. Mironov is a founding figure in global bioprinting and a co-author of a foundational early publication on organ printing (2003); Kovalev is Regentron's Chief Scientific Officer.
In preparation
Manuscripts in preparation
Additional manuscripts from the program will appear here as their status advances. The titles below describe planned work.
Biofabrication
Biocomposite cell aggregates for bone and cartilage regeneration — preclinical evaluation and translation
Regenerative Medicine
In-vivo bioreactor for fingertip regeneration — device architecture and early biological observations
Research pipeline
Defined programs across the regenerative platform
The pipeline makes the near-term translation priorities visible while maintaining a clear distinction between research hypotheses, historical experience, and established evidence.
01
Bone & cartilage
Reparative-osteogenesis spheroids, standardized reference-cell studies, and bone or cartilage cellular applications.
02
Alopecia
Proprietary cellular spheroids and local-delivery research for hair-restoration applications.
03
Ophthalmology
Retina and optic-nerve regeneration research, with prospective documentation and clinical-program design as the evidentiary priority.
04
Neurology
Treatment concepts for stroke, traumatic brain injury, and cerebral palsy, supported by an IP position in preparation.
05
Constructs & implants
Tissue-engineered constructs, implants, kits, and delivery workflows.
06
Partner-enabled bioprinting
In-situ procedural research using third-party or partner bioprinting systems.
Management believes ophthalmology and neurology may offer some of the shortest routes to clinical translation. Historical ophthalmology experience informs the research strategy, but undocumented outcomes are not presented as established clinical evidence.